Occam Recruits Ruben Tommasi, PhD as Chief Scientific Officer for Entact Bio
In September 2024, Occam placed Ruben Tommasi, PhD, as Chief Scientific Officer at Entact Bio, a Qiming, venBio, and Abingworth investment. Entact, led by seasoned biotech entrepreneur Vicky Richon, is developing novel precision medicines that enhance the function of beneficial proteins.
Ruben brings three decades of experience in the life sciences industry, where his leadership drove drug discovery across therapeutic areas at global pharmaceutical companies and innovative biotechs.
Prior to joining Entact Bio, Ruben held the Chief Scientific Officer role at both Dunad Therapeutics and Entasis Therapeutics. Previous roles include leadership positions at AstraZeneca and the Novartis Institutes for Biomedical Research (NIBR).
Enhancing Protein Function with ENTAC Technology
Entact Bio focuses on developing small-molecule drugs called ENTACs (Enhancement-Targeting Chimeras), which enhance the function of beneficial proteins by recruiting specific enzymes (deubiquitinases) to fix issues like protein deficiency or mislocation. Their proprietary Encompass platform integrates biology, chemistry, and computational tools to identify targets, design ENTACs, and select the right enzymes for each. This innovative approach expands the range of treatable diseases by enhancing proteins that are currently undruggable.
Related Placements
Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.